What is the price target for GYRE stock?
9 analysts have analysed GYRE and the average price target is 18.36 USD. This implies a price increase of 140% is expected in the next year compared to the current price of 7.65.
GYRE THERAPEUTICS INC (GYRE) Forecast, Price Target & Analyst Ratings
NASDAQ:GYRE • US4037831033
Current stock price
7.65 USD
+0.15 (+2%)
At close:
7.51 USD
-0.14 (-1.83%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GYRE THERAPEUTICS INC (GYRE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 31, 2026
- Period
- Q4 / 2025
- EPS Estimate
- $0.06
- Revenue Estimate
- 36.145M
Price Target Details & History
Consensus Price Target and Range
Mean target
$18.36
Upside
+ 140.00%
From current price of $7.65 to mean target of $18.36, Based on 9 analyst forecasts
Low
$16.16
Median
$18.36
High
$21.00
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for GYRE. The average price target is 18.36 USD. This implies a price increase of 140% is expected in the next year compared to the current price of 7.65.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.44%
GYRE was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about GYRE.
In the previous month the buy percentage consensus was at a similar level.
GYRE was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-10 | Jefferies | Initiate | Buy |
| 2025-08-26 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 31, 2026
- Period
- Q4 / 2025
- EPS Estimate
- $0.06
- Revenue Estimate
- 36.145M
- Revenue Q2Q
- 29.68%
- EPS Q2Q
- 5,126.38%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
-2.39%
Revenue (3 Months)
-2.39%
EPS (1 Month)
-10.52%
EPS (3 Months)
6.26%
Next Earnings Summary
GYRE is expected to report earnings on 3/31/2026. The consensus EPS estimate for the next earnings is 0.06 USD and the consensus revenue estimate is 36.15M USD.
The next earnings revenue estimate has been revised downward by 2.39% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 790K -89.24% | 113.45M 14,260.76% | 105.757M -6.78% | 118.01M 11.59% | 149.06M 26.31% | 150.25M 0.80% | 451.96M 200.81% | 278.36M -38.41% | 324.56M 16.60% | 403.92M 24.45% | 406.98M 0.76% | 486.54M 19.55% | |
| EBITDA YoY % growth | -29.21M 66.65% | 20.287M 169.45% | 17.778M -12.37% | 20.808M 17.04% | 16.524M -20.59% | 918K -94.44% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -29.41M 66.54% | 19.213M 165.33% | 16.229M -15.53% | 18.207M 12.19% | 9.69M -46.78% | 12.954M 33.68% | 281.42M 2,072.46% | 67.014M -76.19% | 98.226M 46.58% | 117.3M 19.42% | 96.9M -17.39% | 155.04M 60.00% | |
| Operating Margin | -3,722.78% | 16.94% | 15.35% | 15.43% | 6.50% | 8.62% | 62.27% | 24.07% | 30.26% | 29.04% | 23.81% | 31.87% | |
| EPS YoY % growth | N/A 132.70% | N/A -117.39% | N/A 112.87% | 0.19 -40.64% | 0.19 1.82% | 0.04 -78.57% | 2.32 5,575.00% | 0.68 -70.48% | 0.94 37.31% | 1.55 65.22% | 1.43 -7.89% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.06 5,126.38% | 0.08 172.00% | 0.06 206.00% | 0.04 -49.00% | 0.05 -11.77% |
| Revenue Q2Q % growth | 36.145M 29.68% | 35.292M 60.00% | 38.046M 42.12% | 41.004M 34.16% | 45.084M 24.73% |
| EBITDA Q2Q % growth | 9.18M 315.01% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 1.53M 130.77% | 4.998M 119.89% | 2.958M 36.25% | -4.998M -172.17% | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-49.40%
EPS Next 5 Year
16.75%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
6.96%
Revenue Next 5 Year
17.78%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-66.98%
EBIT Next 5 Year
N/A
GYRE THERAPEUTICS INC / GYRE Forecast FAQ
Can you provide the upcoming earnings date for GYRE THERAPEUTICS INC?
GYRE THERAPEUTICS INC (GYRE) will report earnings on 2026-03-31, after the market close.
Can you provide the consensus estimates for GYRE THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of GYRE THERAPEUTICS INC (GYRE) is 0.06 USD and the consensus revenue estimate is 36.15M USD.
What is the number of analysts for GYRE stock?
The number of analysts covering GYRE THERAPEUTICS INC (GYRE) is 9.